European heart journal
Audio Summaries

Targeting trafficking defects in long QT syndrome type 2: a phase 2 clinical study with patient-specific cellular validation

Sep 22, 2026

This study investigates whether lumacaftor (LUM) can effectively shorten the corrected QT interval (QTc) in patients with long QT syndrome type 2 (LQT2) caused by trafficking defects in the KCNH2 gene. The phase 2 clinical trial demonstrated that LUM significantly reduced QTc in patients, particularly those with higher baseline QTc values, and showed a correlation between clinical outcomes and cellular mechanisms in patient-specific cardiomyocytes. The findings suggest that LUM may serve as a promising mechanism-targeted therapy for LQT2, supporting the use of precision medicine in treating inherited arrhythmia syndromes.

Intracranial haemorrhage following tenecteplase fibrinolysis for acute myocardial infarction

Sep 21, 2026

The authors aimed to identify risk factors for intracranial hemorrhage (ICH) following tenecteplase (TNK) administration in patients with ST-elevation myocardial infarction (STEMI) and to develop a clinical risk prediction tool. Their analysis of data from six randomized controlled trials revealed that higher systolic blood pressure, increasing age, female sex, and lower body weight were associated with an elevated risk of ICH. The findings suggest that optimizing blood pressure and considering dose adjustments of TNK in older patients may help mitigate this risk.

Whole-grain consumption and cardiometabolic risk: a meta-analysis of randomized trials

Sep 15, 2026

The authors aimed to investigate the relationship between whole-grain consumption and cardiometabolic risk factors through a meta-analysis of randomized trials. They found that an increase of 48 g/day in whole-grain intake was associated with significant reductions in body weight, waist circumference, total cholesterol, and other cardiometabolic markers, particularly at intakes of approximately 60-100 g/day. However, the certainty of evidence varied across different outcomes, and data on higher intake levels were limited.

Exercise stress echocardiography for diagnosis of heart failure with preserved ejection fraction: a multicentre study

Sep 10, 2026

This study investigates whether exercise stress echocardiography can enhance the diagnosis of heart failure with preserved ejection fraction (HFpEF) compared to existing diagnostic algorithms. The authors found that while current non-invasive methods have limited sensitivity, incorporating resting left atrial compliance significantly improved diagnostic accuracy, allowing for better classification of patients and reducing the need for invasive testing. Ultimately, the study suggests that while exercise echocardiography can aid in diagnosis, it cannot fully replace invasive methods.

Nighttime light exposure and cardiac structure and function

Sep 9, 2026

The authors aimed to investigate the impact of nighttime light exposure on cardiac structure and function, as well as its association with cardiovascular disease (CVD) outcomes. Their findings revealed that higher nighttime light exposure was linked to adverse cardiac remodeling, subclinical functional decline, and an increased risk of various CVD events, suggesting that reduced sleep duration may mediate these effects. This research underscores the importance of minimizing nighttime light exposure for cardiovascular health.

Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial

Sep 6, 2026

The TARGET-D trial aimed to determine whether targeted vitamin D supplementation could reduce major adverse cardiovascular events in patients following a myocardial infarction. Despite high prevalence of vitamin D insufficiency among participants, the study found no significant difference in major cardiovascular outcomes between those receiving targeted vitamin D management and those receiving usual care. However, a notable reduction in myocardial infarction rates was observed in the vitamin D group compared to usual care.

Quality standards for preclinical research in cardio-oncology

Sep 6, 2026

The authors aim to establish quality standards for preclinical research in cardio-oncology, specifically addressing cancer therapy-related cardiovascular toxicity (CTR-CVT). They highlight the need for a systematic approach to experimental model selection and reporting methods, advocating for first-tier and second-tier standards to enhance the reliability and reproducibility of studies. By promoting these standards, the authors hope to advance research in this field, improve funding allocation, and support the development of new cancer therapies.

Reconciling evidence-based and personalized medicine: perspectives in heart failure and cardiomyopathies

Sep 6, 2026

The authors explore how to reconcile evidence-based medicine (EBM) with personalized medicine (PM) in the management of heart failure and inherited cardiomyopathies, given the tension between population averages and individual patient needs. They examine the philosophical and practical implications of this interplay and propose a framework to harmonize both approaches, aiming to enhance patient outcomes in cardiovascular care. The review highlights the need for strategies that integrate the strengths of EBM and PM, particularly in the context of conditions with variable individual trajectories.

Subclinical liver disease and incident cardiovascular events

Sep 6, 2026

This study investigates the independent and combined effects of hepatic steatosis, fibrosis, and functional decline on the risk of developing cardiovascular disease (CVD) in a large cohort of participants without pre-existing liver or CVD. The authors found that all three non-invasive liver biomarkers significantly predicted CVD risk, with a notably higher risk observed in individuals with elevated levels across all three measures. These findings suggest that subclinical liver disease is a critical factor in CVD risk assessment, highlighting the potential for these biomarkers to enhance risk stratification and inform prevention strategies.

Ischaemic stroke in atrial flutter vs fibrillation: a Finnish nationwide study

Sep 3, 2026

The authors aimed to compare the risk of ischaemic stroke (IS) between patients with atrial flutter (AFL) and those with atrial fibrillation (AF) using a large Finnish registry. Their findings indicate that patients with AFL-only have a significantly lower risk of IS compared to those with AF-only, suggesting important differences in thromboembolic risk associated with these arrhythmias. The study highlights the need for tailored anticoagulation strategies based on the type of atrial arrhythmia.